Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1331-1334

  Xiao, Jiuchang ^a   He, Xiaoyan ^a   Wang, Zengyan ^b   Hu, Jiying ^c   Sun, Fang ^c   Qi, Feng ^c   Yang, Shugang ^b   Xiao, Zhenyu ^a  

^a Department of Intensive Care Unit   (China)

^b People's Hospital of Zhucheng   (China)

^c Maternal and Children Health's Hospital   (China)

Author keywords

Carbohydrate antigen 19 9; Gastric cancer; Meta analysis; Survival

Indexed keywords

CA 19-9 ANTIGEN;

ANTIGEN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; HUMAN; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER;

CA-19-9 ANTIGEN; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84899069861     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1177-1     Document Type: Article

References (22)

1. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-90.
2. Polk DB, Peek Jr RM. Helicobacter pylori : gastric cancer and beyond. Nat Rev Cancer. 2010;10:403-14.
3. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2:98-107. (Pubitemid 40790143)
4. Higuchi K, Tanabe S, Azuma M, Sasaki T, Ishido K, Koizumi W. Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status. Pathobiology. 2011;78:334-42.
5. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:e1-48.
6. DuffyMJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-7.
7. Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2013;22:4-11.
8. Nam DH, Lee YK, Park JC, Lee H, Shin SK, Lee SK, Lee YC, Cheong JH, Hyung WJ, Noh SH, Kim CB: Prognostic value of early postoperative tumor marker response in gastric cancer. Ann Surg Oncol 2013
9. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Surgical resection of stage IV gastric cancer and prognosis. Anticancer Res. 2007;27:4381-6.
10. Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012;107:275-9.
11. Duraker N. Naci Celik A, Gencler N: The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients. Eur J Surg Oncol. 2002;28:844-9. (Pubitemid 35402295)
12. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154-61.
13. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol. 2001;32:41-4. (Pubitemid 32038110)
14. Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76:266-71. (Pubitemid 32381683)
15. GasparMJ, Arribas I, CocaMC, Diez-AlonsoM. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001;22:318-22. (Pubitemid 32823950)
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. (Pubitemid 37088507)
17. DerSimonian R, LairdN.Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
18. Mantel N, HaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
19. Jo JC, Ryu MH, Koo DH, Ryoo BY, Kim HJ, Kim TW, Choi KD, Lee GH, Jung HY, Yook JH, Oh ST, Kim BS, Kim JH, Kang YK: Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia Pac J Clin Oncol 2012
20. Kochi M, FujiiM, Kanamori N, Kaiga T, Kawakami T, Aizaki K, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177-86. (Pubitemid 32290724)
21. Liu X, Cai H, Wang Y. Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol. 2012;10:68.
22. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16:105-10. (Pubitemid 32591564)